Autologous adipose tissue implant with concentrated stem cells

• US 8,119,121 B2
• Filed: 07/07/2003
• Issued: 02/21/2012
• Est. Priority Date: 12/07/2001
• Status: Expired due to Fees

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H.
• Primary Examiner(s): Lankford, L Blaine
• Application Number:
  US10/614,648
• Publication Number:
  US 20050260174A1
• Time in Patent Office: 3,151 Days
• Field of Search: 424/93.7, 424/325, 424/366, 606/1, 606/131, 604/19, 604/22
• US Class Current: 424/93.7
• CPC Class Codes: A61B 10/0283 with vacuum aspiration, e.g. caused by retractable plunger or by connected syringe A61B10/025, A61B10/0266 take precedence
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61M 1/76 Handpieces specially for suction-irrigation A61M1/774, aspiration tips A61M1/84
• CPC Class Codes: A61M 2202/08 Lipoids
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12M 47/04 : Cell isolation or sorting purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04
• CPC Class Codes: C12N 2506/1384 : from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 : Vascular Endothelial cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Claims

1. An autologous adipose tissue implant comprising:

a first portion of intact (non-disaggregated) adipose tissue removed from a patient mixed with a concentrated population of adipose-derived cells that comprises stem cells,

wherein the population of adipose-derived cells comprising stem cells is concentrated from a second portion of adipose tissue removed from the same patient, and

wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 1.7×

10⁵ cells/ml.

2. The autologous adipose tissue implant of claim 1, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.1×

10⁵ cells/ml.

3. The autologous adipose tissue implant of claim 1, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.5×

10⁵ cells/ml.

4. The adipose tissue implant of claim 1, further comprising an additive.

5. The adipose tissue implant of claim 4, wherein said additive is selected from the group consisting of growth factors, cytokines, a preformed matrix, cells, tissue, tissue fragments, disaggregating agents, antimicrobial agents, scaffolds, immunosuppressive agents, and antibiotics, or any combination thereof.

6. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is not cultured.

7. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is cultured.

8. The adipose tissue implant of claim 1, wherein said concentrated population of adipose-derived cells that comprises stem cells is isolated in a closed, sterile fluid/tissue pathway.

9. The adipose tissue implant of claim 1, wherein the first, second, or both portions are cryopreserved after removal from the patient.

10. An autologous adipose tissue implant, comprising:

a first portion of intact (non-disaggregated) adipose tissue comprising connective tissue removed from a patient, mixed with a concentrated population of adipose-derived cells that comprises stem cells, wherein the population of adipose-derived cells comprising stem cells is concentrated from a second portion of adipose tissue that is removed from the same patient and enzymatically treated, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 1.7×

10⁵ cells/ml.

11. The autologous adipose tissue implant of claim 10, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.1×

10⁵ cells/ml.

12. The autologous adipose tissue implant of claim 10, wherein the stem cell concentration in the concentrated population of adipose-derived cells that comprises stem cells is more than 2.5×

10⁵ cells/ml.

13. The adipose tissue implant of claim 10, further comprising an additive.

14. The adipose tissue implant of claim 13, wherein said additive is selected from the group consisting of growth factors, cytokines, a preformed matrix, cells, tissue, tissue fragments, disaggregating agents, antimicrobial agents, scaffolds, immunosuppressive agents, and antibiotics, or any combination thereof.

15. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is not cultured.

16. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is cultured.

17. The adipose tissue implant of claim 10, wherein said concentrated population of adipose-derived cells that comprises stem cells is isolated in a closed, sterile fluid/tissue pathway.

18. The adipose tissue implant of claim 10, wherein the first, second, or both portions are cryopreserved after removal from the patient.